Companies in #Dermatology

Develops topical treatments for chronic skin diseases including psoriasis and atopic dermatitis using proprietary drug delivery technologies.

Shanghai Ark Biopharmaceutical (ArkBio) is a clinical-stage biotech developing antiviral therapeutics, including ziresovir, an RSV antiviral drug.

Clinical-stage biotechnology company developing next-generation bispecific antibodies for immunology and inflammation (I&I) disorders, including dermatology, respiratory, gastroenterology and rheumatology.

Bausch Health Companies Inc. (NYSE: BHC) is a diversified specialty pharmaceutical and medical device company headquartered in Laval, Quebec, operating through five reporting segments: Salix (gastroenterology), International, Solta Medical (aesthetic devices), Diversified, and Bausch + Lomb. Its products span gastroenterology, hepatology, neurology, dermatology, dentistry, over-the-counter medicines, aesthetic devices and eye health, sold across the United States, Canada, Europe, China, Japan, Mexico and other markets. The company traces its lineage to ICN Pharmaceuticals, founded in 1960, which became Valeant Pharmaceuticals International and was renamed Bausch Health Companies in July 2018. Q3 2026 revenue was $2.90 billion with adjusted earnings per share of $1.77, and management raised full-year 2026 guidance to $5.525–5.625 billion of revenue and $3.225–3.275 billion of adjusted EBITDA. The equity carries roughly $18 billion of net debt against a market capitalisation near $3.3 billion, which makes balance-sheet actions — debt repurchase, refinancing and deleveraging — as important to the share price as quarterly earnings.

Botanix Pharmaceuticals is a commercial-stage dermatology company developing novel treatments for serious skin conditions. Its lead product, Sofdra (sofpironium bromide gel, 12.45%), is the first FDA-approved new chemical entity for primary axillary hyperhidrosis.

Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies targeting inflammatory and allergic diseases. Recently scrapped its antibody for prurigo nodularis after a Phase 2 flop.

Clinical-stage biopharmaceutical company developing therapies for T cell-driven inflammatory diseases, led by rademikibart (CBP-201), an IL-4R alpha antibody in late-stage development for atopic dermatitis, asthma and COPD.

DifGen Pharmaceuticals is a specialty pharma company. See today's news for the latest developments.

Clinical-stage biotechnology company developing RNA-based immune activators that turn cold tumors hot, led by intralesional BO-112 for skin tumors and other solid tumors.

Leo Pharma is a privately held Danish dermatology company developing treatments for skin diseases including psoriasis, eczema, and rare conditions like generalized pustular psoriasis (GPP).

Oak Hill Bio is a dermatology company. See today's news for the latest developments.

Phothera is a phototherapy medical device company. Recently announced that Aetna updated its coverage policy to include home phototherapy for vitiligo treatment, effective July 2026.

Pierre Fabre is a French pharmaceutical and dermo-cosmetics group whose portfolio spans oncology, dermatology, rare diseases and consumer health, and whose cell therapy tabelecleucel is under FDA review for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

Biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Its lead asset LISRAYA (brepocitinib) received FDA approval for dermatomyositis, with Orsini Specialty Pharmacy serving as the specialty pharmacy partner.

Sensus Healthcare is a medical device company that designs, manufactures and sells superficial radiation therapy (SRT) systems — low-energy X-ray devices used as a non-surgical alternative for treating non-melanoma skin cancers including basal cell and squamous cell carcinoma, as well as keloids and other dermatological conditions. Its product line spans the SRT-100, the SRT-100 Vision system with embedded high-frequency ultrasound imaging and treatment planning, and the SRT-100+, supported by the Sentinel service programme and a Transdermal Infusion system. The company sells primarily into private dermatology practices and to radiation oncologists in both private and hospital settings, and its commercial model is closely tied to US reimbursement: dedicated superficial-radiotherapy CPT codes took effect on 1 January 2026 and CMS has proposed a 26% increase in the hospital-based delivery code. Sensus was incorporated in 2010, is headquartered in Boca Raton, Florida, employs roughly 60 people and has traded on Nasdaq since its June 2016 IPO.

Clinical-stage immunoregulatory therapeutics company built on tissue regulatory T cell biology, combining high-resolution human tissue sequencing, computational biology and translational assay systems in its Deep Biology platform.

Washington, DC-based biopharmaceutical company developing and commercializing therapies for central nervous system disorders, dermatologic conditions, and rare diseases, with three FDA-approved products on market.

New Haven, CT-based dermatology biotech developing dissolvable microarray patches for pattern hair loss (androgenetic alopecia), with a clinical-stage lead candidate.